Mira Pharmaceuticals announces preclinical data on oral Mira-55

MIRA Pharmaceuticals (MIRA) announced new preclinical data showing that oral Mira-55 normalized pain and significantly reduced inflammation, outperforming injected morphine in an established animal model of inflammatory pain. This study marks the first time inflammation was directly measured alongside pain in MIRA’s Mira-55 program. In the Company’s prior study, only pain sensitivity was evaluated, with both Mira-55 and morphine administered by injection. The new data expand those findings by demonstrating that oral administration of Mira-55 provided superior pain normalization and direct anti-inflammatory effects, whereas morphine produced only partial and indirect inflammation reduction. Pain sensitivity was assessed using Von Frey Filament testing, and inflammation was quantified by paw-edema volume in the formalin-induced inflammatory pain model. Results: Oral Mira-55 normalized pain thresholds, fully restoring withdrawal responses to baseline and outperformed injected morphine. Mira-55 significantly reduced inflammation, confirming a direct CB2 receptor-mediated anti-inflammatory mechanism, while morphine showed only partial, centrally mediated effects. Both treatments provided pain relief, but Mira-55 delivered dual anti-inflammatory and analgesic benefits without sedation or opioid-related risks. These findings build on previously reported data showing that injected Mira-55 achieved morphine-comparable pain relief, while this new study demonstrates that oral Mira-55 achieved superior pain normalization and direct inflammation reduction. Collectively, the results reinforce Mira-55’s potential as a dual-acting, non-opioid therapy that addresses both inflammation and pain through differentiated, CB2-selective mechanisms.